Amy Horton Sells 641 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 641 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $38.02, for a total transaction of $24,370.82. Following the sale, the chief accounting officer directly owned 132,514 shares in the company, valued at approximately $5,038,182.28. The trade was a 0.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amy Horton also recently made the following trade(s):

• On Tuesday, March 3rd, Amy Horton sold 901 shares of Artivion stock. The shares were sold at an average price of $37.78, for a total transaction of $34,039.78.
• On Tuesday, February 24th, Amy Horton sold 830 shares of Artivion stock. The stock was sold at an average price of $35.69, for a total value of $29,622.70.
• On Monday, February 23rd, Amy Horton sold 1,731 shares of Artivion stock. The shares were sold at an average price of $37.59, for a total value of $65,068.29.
• On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The shares were sold at an average price of $44.42, for a total value of $203,088.24.

Artivion Trading Down 0.5%

AORT opened at $38.41 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 192.06 and a beta of 1.60. The business has a fifty day moving average price of $41.42 and a 200 day moving average price of $42.92. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm’s quarterly revenue was up 19.2% on a year-over-year basis. Sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on AORT. Needham & Company LLC reiterated a “buy” rating and set a $58.00 target price on shares of Artivion in a research note on Monday, February 2nd. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Citizens Jmp increased their price objective on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Artivion currently has an average rating of “Moderate Buy” and a consensus target price of $48.97.

Key Headlines Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Institutional Trading of Artivion

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after buying an additional 141,030 shares during the last quarter. Morgan Stanley increased its holdings in shares of Artivion by 0.8% in the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after acquiring an additional 18,248 shares during the period. State Street Corp increased its holdings in shares of Artivion by 2.9% in the 4th quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after acquiring an additional 44,641 shares during the period. Fred Alger Management LLC raised its position in Artivion by 4.2% in the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock valued at $62,603,000 after purchasing an additional 55,322 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after purchasing an additional 748,119 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.